{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:56:26Z","timestamp":1783947386609,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Incubation Project and 1.3.5 Project for Disciplines of Excellence of West China Hospital, Sichuan University","award":["2019HXFH038, 2021HXFH018 and ZYJC21024"],"award-info":[{"award-number":["2019HXFH038, 2021HXFH018 and ZYJC21024"]}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021JDRC0045, 2021YFS0164, 2021JDRC0169"],"award-info":[{"award-number":["2021JDRC0045, 2021YFS0164, 2021JDRC0169"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chengdu Science and Technology Bureau Project","award":["2021-YF05-00677-SN"],"award-info":[{"award-number":["2021-YF05-00677-SN"]}]},{"name":"Major Research and Development Projects of Sichuan Provincial Department of Science and Technology","award":["2024YFFK0062"],"award-info":[{"award-number":["2024YFFK0062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09047-0","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:43:06Z","timestamp":1744274586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy"],"prefix":"10.1007","volume":"68","author":[{"given":"Tao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-1839","authenticated-orcid":false,"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"1","key":"9047_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nan.12380","volume":"43","author":"Y Allenbach","year":"2017","unstructured":"Allenbach Y, Benveniste O, Goebel HH, Stenzel W (2017) Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol 43(1):62\u201381. https:\/\/doi.org\/10.1111\/nan.12380","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"9047_CR2","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai K, Granger B, Amelin D et al (2018) Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75(12):1528\u20131537. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2598","journal-title":"JAMA Neurol"},{"issue":"38","key":"9047_CR3","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e335","volume":"35","author":"GY Ahn","year":"2020","unstructured":"Ahn GY, Suh CH, Kim YG, Park YB, Shim SC, Lee SH, Lee SS, Bae SC, Yoo DH (2020) Efficacy and safety of rituximab in Korean patients with refractory inflammatory myopathies. J Korean Med Sci 35(38). https:\/\/doi.org\/10.3346\/jkms.2020.35.e335","journal-title":"J Korean Med Sci"},{"key":"9047_CR4","doi-asserted-by":"publisher","unstructured":"Manwatkar A, Naresh K, Mathew J, Nair AV, Goel R, Yadav B, Prakash JAJ, Das JK, Sivadasan A (2024) Comparison of rituximab efficacy in treatment-na\u00efve and refractory inflammatory myopathies: experiences from a tertiary care centre. Rheumatology (Oxford) 00:1\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keae307","DOI":"10.1093\/rheumatology\/keae307"},{"issue":"1","key":"9047_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13075-024-03310-z","volume":"26","author":"C Campochiaro","year":"2024","unstructured":"Campochiaro C, Farina N, De Luca G, Batani V, Trignani G, Vignale D, Palmisano A, Matucci-Cerinic M, Dagna L (2024) Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies. Arthritis Res Ther 26(1):79. https:\/\/doi.org\/10.1186\/s13075-024-03310-z","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"9047_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","volume":"106","author":"I Marie","year":"2012","unstructured":"Marie I, Dominique S, Janvresse A, Levesque H, Menard JF (2012) Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 106(4):581\u2013587. https:\/\/doi.org\/10.1016\/j.rmed.2012.01.001","journal-title":"Respir Med"},{"issue":"6","key":"9047_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","volume":"45","author":"TJ Doyle","year":"2018","unstructured":"Doyle TJ, Dhillon N, Madan R et al (2018) Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol 45(6):841\u2013850. https:\/\/doi.org\/10.3899\/jrheum.170541","journal-title":"J Rheumatol"},{"issue":"8","key":"9047_CR8","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, Garen T, Molberg O (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54(8):1420\u20131428. https:\/\/doi.org\/10.1093\/rheumatology\/kev004","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"9047_CR9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So H, Wong VTL, Lao VWN, Pang HT, Yip RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37(7):1983\u20131989. https:\/\/doi.org\/10.1007\/s10067-018-4122-2","journal-title":"Clin Rheumatol"},{"key":"9047_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105983","volume":"172","author":"MM Mao","year":"2020","unstructured":"Mao MM, Xia S, Guo BP, Qian WP, Zheng ZX, Peng XM, Chen RC, Luo Q, Han Q (2020) Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD. Respir Med 172. https:\/\/doi.org\/10.1016\/j.rmed.2020.105983","journal-title":"Respir Med"},{"issue":"1","key":"9047_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-024-03353-2","volume":"26","author":"J Narvaez","year":"2024","unstructured":"Narvaez J, Canadillas E, Castellvi I, Alegre JJ, Vicens-Zygmunt V, Bermudo G, Vidal-Montal P, Molina Molina M, Nolla JM (2024) Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome. Arthritis Res Ther 26(1):122. https:\/\/doi.org\/10.1186\/s13075-024-03353-2","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9047_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(22)00359-9","journal-title":"Lancet Respir Med"},{"issue":"2","key":"9047_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324. https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9047_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","volume":"163","author":"MT Holzer","year":"2023","unstructured":"Holzer MT, Nies JF, Oqueka T, Huber TB, Kotter I, Krusche M (2023) Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis. Chest 163(1):e1\u2013e5. https:\/\/doi.org\/10.1016\/j.chest.2022.08.2209","journal-title":"Chest"},{"issue":"3","key":"9047_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003238","volume":"9","author":"L Ostendorf","year":"2023","unstructured":"Ostendorf L, Muench F, Thormahlen L, Galbavy Z, Korner R, Nee J, Schneider U (2023) Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab. RMD Open 9(3). https:\/\/doi.org\/10.1136\/rmdopen-2023-003238","journal-title":"RMD Open"},{"key":"9047_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223541","author":"O Landon-Cardinal","year":"2023","unstructured":"Landon-Cardinal O, Allard-Chamard H, Chapdelaine H, Doucet S, Rich E, Bourre-Tessier J (2023) Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2022-223541","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"9047_CR17","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R et al (2023) CD19-Targeting CAR-T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162. https:\/\/doi.org\/10.1001\/jama.2023.8753","journal-title":"JAMA"},{"issue":"10379","key":"9047_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F Muller","year":"2023","unstructured":"Muller F, Boeltz S, Knitza J et al (2023) CD19-targeted CAR-T cells in refractory antisynthetase syndrome. Lancet 401(10379):815\u2013818. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5","journal-title":"Lancet"},{"issue":"1","key":"9047_CR19","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, Muller F et al (2024) Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford) 63(1):e12\u2013e14. https:\/\/doi.org\/10.1093\/rheumatology\/kead330","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9047_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong MH, Zhou LQ et al (2024) Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A 121(6). https:\/\/doi.org\/10.1073\/pnas.2315990121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"9047_CR21","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890-4904 e4899. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"9047_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.777502","volume":"12","author":"BB Cui","year":"2021","unstructured":"Cui BB, Tian YR, Ma XY, Yin G, Xie Q (2021) Belimumab for immune-mediated necrotizing myopathy associated with anti-SRP antibodies: a case report and retrospective review of patients treated with anti-B-cell therapy in a single center and literature. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.777502","journal-title":"Front Immunol"},{"key":"9047_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead281","author":"G Marder","year":"2023","unstructured":"Marder G, Quach T, Chadha P et al (2023) Belimumab treatment of adult idiopathic inflammatory myopathy. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kead281","journal-title":"Rheumatology (Oxford)"},{"key":"9047_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.04.060","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li Y, Shen T, Zhang H, Luo S, Zhang Q, Dang X, Li X, Long H (2024) Belimumab ameliorates symptoms and disease activity in dermatomyositis and juvenile dermatomyositis patients refractory to standard therapy: a retrospective observational study. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.060","journal-title":"J Am Acad Dermatol"},{"key":"9047_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae601","author":"H Gao","year":"2024","unstructured":"Gao H, Lin J, Yang M, Gui M, Ji S, Bu B, Li Y (2024) Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keae601","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"9047_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S et al (2024) BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med 391(9):867\u2013869. https:\/\/doi.org\/10.1056\/NEJMc2408786","journal-title":"N Engl J Med"},{"key":"9047_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447182","volume":"15","author":"M Yang","year":"2024","unstructured":"Yang M, Yuan J, Wang Y, Hao H, Zhang W, Wang Z, Yuan Y, Zhao Y (2024) Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod. Front Immunol 15. https:\/\/doi.org\/10.3389\/fimmu.2024.1447182","journal-title":"Front Immunol"},{"issue":"11","key":"9047_CR28","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","volume":"65","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O\u2019Connor KC, Amato AA (2005) Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65(11):1782\u20131787. https:\/\/doi.org\/10.1212\/01.wnl.0000187124.92826.20","journal-title":"Neurology"},{"issue":"11","key":"9047_CR29","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2024-225773","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez I, Mu\u00f1oz-Braceras S, Casal-Dominguez M et al (2024) Pathological autoantibody internalisation in myositis. Ann Rheum Dis 83(11):1549\u20131560. https:\/\/doi.org\/10.1136\/ard-2024-225773","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9047_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.24902","volume":"81","author":"L Arouche-Delaperche","year":"2017","unstructured":"Arouche-Delaperche L, Allenbach Y, Amelin D et al (2017) Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81(4):538\u2013548. https:\/\/doi.org\/10.1002\/ana.24902","journal-title":"Ann Neurol"},{"issue":"7","key":"9047_CR31","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/rheumatology\/keac602","volume":"62","author":"DC Anang","year":"2023","unstructured":"Anang DC, Walter HAW, Lim J et al (2023) B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies. Rheumatology (Oxford) 62(7):2585\u20132593. https:\/\/doi.org\/10.1093\/rheumatology\/keac602","journal-title":"Rheumatology (Oxford)"},{"key":"9047_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead597","author":"J He","year":"2023","unstructured":"He J, Liu Z, Cao Y et al (2023) Single-cell landscape of peripheral immune response in patients with anti-melanoma differentiation-associated gene 5 dermatomyositis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kead597","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"9047_CR33","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S et al (2022) Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun 13(1):6458. https:\/\/doi.org\/10.1038\/s41467-022-34145-4","journal-title":"Nat Commun"},{"issue":"1","key":"9047_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua C, Chiavelli H, Allenbach Y et al (2019) In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78(1):131\u2013139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213518","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9047_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","volume":"144","author":"C Preusse","year":"2022","unstructured":"Preusse C, Paesler B, Nelke C et al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 144(2):353\u2013372. https:\/\/doi.org\/10.1007\/s00401-022-02438-z","journal-title":"Acta Neuropathol"},{"issue":"2","key":"9047_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/acr2.11521","volume":"5","author":"Y Sugimori","year":"2023","unstructured":"Sugimori Y, Iwasaki Y, Takeshima Y et al (2023) Transcriptome profiling of immune cell types in peripheral blood reveals common and specific pathways involved in the pathogenesis of myositis-specific antibody-positive inflammatory myopathies. ACR Open Rheumatol 5(2):93\u2013102. https:\/\/doi.org\/10.1002\/acr2.11521","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"9047_CR37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/1756-185X.12736","volume":"18","author":"SA Haq","year":"2015","unstructured":"Haq SA, Tournadre A (2015) Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets. Int J Rheum Dis 18(8):818\u2013825. https:\/\/doi.org\/10.1111\/1756-185X.12736","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"9047_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","volume":"56","author":"S Fasano","year":"2017","unstructured":"Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA (2017) Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 56(1):26\u201336. https:\/\/doi.org\/10.1093\/rheumatology\/kew146","journal-title":"Rheumatology (Oxford)"},{"key":"9047_CR39","doi-asserted-by":"publisher","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, Allen A Jr, Assassi S, Buckley L, Chami HA, Corwin DS, Dellaripa PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB, Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss B, Chowdhary V, Dematte D'Amico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Lakin KS, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I (2024) 2023 American college of rheumatology (ACR)\/american college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76(8):1182-1200. https:\/\/doi.org\/10.1002\/art.42861","DOI":"10.1002\/art.42861"},{"key":"9047_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609","volume":"13","author":"C Zhen","year":"2022","unstructured":"Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C (2022) Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.1051609","journal-title":"Front Immunol"},{"issue":"10","key":"9047_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103406","volume":"12","author":"Y Jang","year":"2023","unstructured":"Jang Y, Yoon HY, Kim HS (2023) The efficacy and safety of rituximab in patients with idiopathic inflammatory myopathy-associated interstitial lung disease: case series. J Clin Med 12(10). https:\/\/doi.org\/10.3390\/jcm12103406","journal-title":"J Clin Med"},{"issue":"1","key":"9047_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12931-022-02082-x","volume":"23","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Gao Y, Petnak T, Cheungpasitporn W, Thongprayoon C, Zhang X, Moua T (2022) Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis. Respir Res 23(1):164. https:\/\/doi.org\/10.1186\/s12931-022-02082-x","journal-title":"Respir Res"},{"issue":"6","key":"9047_CR43","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","volume":"40","author":"Y Ge","year":"2021","unstructured":"Ge Y, Li S, Tian X, He L, Lu X, Wang G (2021) Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol 40(6):2311\u20132317. https:\/\/doi.org\/10.1007\/s10067-020-05530-5","journal-title":"Clin Rheumatol"},{"issue":"10","key":"9047_CR44","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D et al (2022) Anti-CD19 CAR-T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"issue":"8","key":"9047_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L et al (2024) CD19 CAR-T cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"issue":"3","key":"9047_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1073191115606205","volume":"24","author":"S Gordts","year":"2017","unstructured":"Gordts S, Uzieblo K, Neumann C, Van den Bussche E, Rossi G (2017) Validity of the self-report psychopathy scales (SRP-III full and short versions) in a community sample. Assessment 24(3):308\u2013325. https:\/\/doi.org\/10.1177\/1073191115606205","journal-title":"Assessment"},{"issue":"6","key":"9047_CR47","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T et al (2024) Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med 30(6):1593\u20131601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1","journal-title":"Nat Med"},{"issue":"7","key":"9047_CR48","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3109\/10428194.2010.483299","volume":"51","author":"WR Hartman","year":"2010","unstructured":"Hartman WR, Pelleymounter LL, Moon I et al (2010) CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leuk Lymphoma 51(7):1315\u20131325. https:\/\/doi.org\/10.3109\/10428194.2010.483299","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"9047_CR49","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/jcp.30760","volume":"237","author":"F Zeng","year":"2022","unstructured":"Zeng F, Zhang J, Jin X, Liao Q, Chen Z, Luo G, Zhou Y (2022) Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases. J Cell Physiol 237(7):2796\u20132807. https:\/\/doi.org\/10.1002\/jcp.30760","journal-title":"J Cell Physiol"},{"key":"9047_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113395","volume":"153","author":"W Li","year":"2022","unstructured":"Li W, Liang L, Liao Q, Li Y, Zhou Y (2022) CD38: An important regulator of T cell function. Biomed Pharmacother 153. https:\/\/doi.org\/10.1016\/j.biopha.2022.113395","journal-title":"Biomed Pharmacother"},{"key":"9047_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.775649","volume":"12","author":"W Li","year":"2022","unstructured":"Li W, Li Y, Jin X, Liao Q, Chen Z, Peng H, Zhou Y (2022) CD38: A significant regulator of macrophage function. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.775649","journal-title":"Front Oncol"},{"issue":"16","key":"9047_CR52","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.vaccine.2009.02.015","volume":"27","author":"R Trepiakas","year":"2009","unstructured":"Trepiakas R, Pedersen AE, Met O, Svane IM (2009) Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 27(16):2213\u20132219. https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.015","journal-title":"Vaccine"},{"issue":"4","key":"9047_CR53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41416-022-02052-6","volume":"128","author":"L Gao","year":"2023","unstructured":"Gao L, Du X, Li J, Qin FX (2023) Evolving roles of CD38 metabolism in solid tumour microenvironment. Br J Cancer 128(4):492\u2013504. https:\/\/doi.org\/10.1038\/s41416-022-02052-6","journal-title":"Br J Cancer"},{"key":"9047_CR54","doi-asserted-by":"publisher","unstructured":"Heimes AS, Riedel N, Almstedt K et al (2023) Prognostic impact of CD38- and IgkappaC-positive tumor-infiltrating plasma cells in triple-negative breast cancer. Int J Mol Sci 24(20). https:\/\/doi.org\/10.3390\/ijms242015219","DOI":"10.3390\/ijms242015219"},{"key":"9047_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9003902","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu J, Zhang H, Wu C (2022) The Regulation between CD4(+)CXCR5(+) Follicular Helper T (Tfh) Cells and CD19(+)CD24(hi)CD38(hi) regulatory B (Breg) cells in gastric cancer. J Immunol Res 2022. https:\/\/doi.org\/10.1155\/2022\/9003902","journal-title":"J Immunol Res"},{"key":"9047_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.890402","volume":"9","author":"M Kanayama","year":"2022","unstructured":"Kanayama M, Luo J (2022) CD38-Induced apoptosis and mitochondrial damage is restored by nicotinamide in prostate cancer. Front Mol Biosci 9. https:\/\/doi.org\/10.3389\/fmolb.2022.890402","journal-title":"Front Mol Biosci"},{"key":"9047_CR57","doi-asserted-by":"publisher","unstructured":"Verhoeven D, Grinwis L, Marsman C, Jansen MH, Consortium TB, Van Leeuwen EM, Kuijpers TW (2023) B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses. Life Sci Alliance 6(9). https:\/\/doi.org\/10.26508\/lsa.202302214","DOI":"10.26508\/lsa.202302214"},{"issue":"12","key":"9047_CR58","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P et al (2020) Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 383(12):1149\u20131155. https:\/\/doi.org\/10.1056\/NEJMoa2023325","journal-title":"N Engl J Med"},{"issue":"6","key":"9047_CR59","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkova","year":"2009","unstructured":"Krystufkova O, Vallerskog T, Helmers SB et al (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68(6):836\u2013843. https:\/\/doi.org\/10.1136\/ard.2008.091405","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9047_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","volume":"20","author":"O Krystufkova","year":"2018","unstructured":"Krystufkova O, Hulejova H, Mann HF, Pecha O, Putova I, Ekholm L, Lundberg IE, Vencovsky J (2018) Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Arthritis Res Ther 20(1):158. https:\/\/doi.org\/10.1186\/s13075-018-1650-8","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9047_CR61","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-024-03153-6","volume":"19","author":"Y Shi","year":"2024","unstructured":"Shi Y, You H, Liu C et al (2024) Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis. Orphanet J Rare Dis 19(1):170. https:\/\/doi.org\/10.1186\/s13023-024-03153-6","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9047_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-020-01431-7","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang W, Liu Y, Wang Z, Yuan Y (2020) Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies. Orphanet J Rare Dis 15(1):181. https:\/\/doi.org\/10.1186\/s13023-020-01431-7","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"9047_CR63","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","volume":"16","author":"O Kry\u0161t\u016ffkov\u00e1","year":"2014","unstructured":"Kry\u0161t\u016ffkov\u00e1 O, Barbasso Helmers S, Venalis P, Malmstr\u00f6m V, Lindroos E, Vencovsk\u00fd J, Lundberg IE (2014) Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies. Arthritis Res Ther 16(5):454. https:\/\/doi.org\/10.1186\/s13075-014-0454-8","journal-title":"Arthritis Res Ther"},{"issue":"1\u20132","key":"9047_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","volume":"249","author":"A Baek","year":"2012","unstructured":"Baek A, Park HJ, Na SJ, Shim DS, Moon JS, Yang Y, Choi YC (2012) The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 249(1\u20132):96\u2013100. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.04.006","journal-title":"J Neuroimmunol"},{"key":"9047_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177721","volume":"14","author":"PO Carstens","year":"2023","unstructured":"Carstens PO, Mullar LM, Wrede A, Zechel S, Wachowski MM, Brandis A, Krause S, Zierz S, Schmidt J (2023) Skeletal muscle fibers produce B-cell stimulatory factors in chronic myositis. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1177721","journal-title":"Front Immunol"},{"issue":"14","key":"9047_CR66","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","volume":"126","author":"H Einsele","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM (2020) The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126(14):3192\u20133201. https:\/\/doi.org\/10.1002\/cncr.32909","journal-title":"Cancer"},{"issue":"6","key":"9047_CR67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"issue":"1","key":"9047_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 13(1):125. https:\/\/doi.org\/10.1186\/s13045-020-00962-7","journal-title":"J Hematol Oncol"},{"issue":"14","key":"9047_CR69","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J et al (2022) Trial of intravenous immune globulin in dermatomyositis. N Engl J Med 387(14):1264\u20131278. https:\/\/doi.org\/10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"issue":"3","key":"9047_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82(3):341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"9047_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead298","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L et al (2023) Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kead298","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09047-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:43:07Z","timestamp":1744274587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09047-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9047"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09047-0","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"22 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for the publication of this study and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"40"}}